Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Change in Receivables (2022 - 2025)

Historic Change in Receivables for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q3 2025 value amounting to $3.1 million.

  • Mirum Pharmaceuticals' Change in Receivables fell 6116.05% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.9 million, marking a year-over-year increase of 9284.4%. This contributed to the annual value of $11.4 million for FY2024, which is 7401.65% down from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Change in Receivables is $3.1 million, which was down 6116.05% from $9.1 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Change in Receivables high stood at $20.1 million for Q4 2023, and its period low was -$13.0 million during Q1 2024.
  • Moreover, its 4-year median value for Change in Receivables was $7.7 million (2022), whereas its average is $7.0 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Change in Receivables soared by 43293.57% in 2023, and later plummeted by 204437.78% in 2024.
  • Mirum Pharmaceuticals' Change in Receivables (Quarter) stood at $7.7 million in 2022, then soared by 162.95% to $20.1 million in 2023, then plummeted by 46.04% to $10.9 million in 2024, then crashed by 71.04% to $3.1 million in 2025.
  • Its Change in Receivables was $3.1 million in Q3 2025, compared to $9.1 million in Q2 2025 and $16.8 million in Q1 2025.